Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.51 | $5,360 | -$1M |
| 2026 Q1 | -0.63 | $2,680 | -$2M |
| 2025 Q4 | -0.80 | $3,555 | -$1M |
| 2025 Q3 | -0.98 | $2,855 | -$2M |
| 2025 Q2 | -0.97 | $7,475 | -$2M |
| 2025 Q1 | -0.97 | $940 | -$1M |
| 2024 Q4 |
| -0.06 |
| $4,512 |
| -$1M |
| 2024 Q3 | -1.73 | $6,580 | -$1M |